Enveric Biosciences (NASDAQ:ENVB – Get Free Report) is projected to release its earnings data before the market opens on Tuesday, May 13th. Analysts expect Enveric Biosciences to post earnings of ($3.45) per share for the quarter.
Enveric Biosciences Trading Up 0.8%
Enveric Biosciences stock opened at $1.28 on Monday. The firm has a 50 day moving average of $1.42 and a 200 day moving average of $3.53. The firm has a market capitalization of $3.16 million, a price-to-earnings ratio of -0.03 and a beta of 0.68. Enveric Biosciences has a 12-month low of $1.01 and a 12-month high of $14.18.
Analysts Set New Price Targets
Separately, HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of Enveric Biosciences in a report on Thursday, March 6th.
About Enveric Biosciences
Enveric Biosciences, Inc, a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health.
Further Reading
- Five stocks we like better than Enveric Biosciences
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- Constellation Powers Up With Reinforced AI Data Center Strategy
- With Risk Tolerance, One Size Does Not Fit All
- Top Analyst-Rated Healthcare Stocks to Watch Now
- What is the Nasdaq? Complete Overview with History
- GlobalFoundries Stock Hits Bottom: Is a Rebound Coming?
Receive News & Ratings for Enveric Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enveric Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
